CJC-1295 vs MK-677 (Ibutamoren)

A synthetic GHRH analogue that stimulates pituitary growth hormone release. The short-acting form (no DAC) is typically paired with a ghrelin agonist like ipamorelin.

An orally active ghrelin receptor agonist that mimics growth hormone secretagogues without injections. Technically a small molecule, but included because it dominates GH-secretagogue conversations alongside CJC-1295/ipamorelin.

CJC-1295 is a modified fragment of growth-hormone releasing hormone (residues 1–29) with four amino-acid substitutions that extend its half-life. The "no DAC" variant lacks the drug affinity complex tag and therefore has a shorter duration, producing physiological GH pulses.

MK-677 binds the ghrelin receptor (GHSR-1a), triggering GH and IGF-1 elevation. Unlike peptide secretagogues, it's orally bioavailable.

100–200 mcg, 1–3 times daily (research protocols)

10–25 mg oral, once daily (usually bedtime)

~30 minutes (no DAC); ~7 days (with DAC)

~24 hours

Subcutaneous

Oral

research-only

research-only

£22 · £11/mg via Peptides UK

Not yet listed